Immunotherapy against several tumors, such as lung cancer, including NSCLC

Patent metadata

Field	Value
Publication number	US-9943579-B2
Application number	US-201715639058-A
Country	US
Kind code	B2
Filing date	Jun 30, 2017
Priority date	Aug 5, 2013
Publication date	Apr 17, 2018
Grant date	Apr 17, 2018

Abstract

A method of treating a patient who has non-small cell lung carcinoma (NSCLC), lung cancer, gastric cancer, and/or glioblastoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has NSCLC, lung cancer, gastric cancer, and/or glioblastoma. A method of treating a patient who has NSCLC, lung cancer, gastric cancer, and/or glioblastoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the NSCLC, lung cancer, gastric cancer, and/or glioblastoma.

First claim

The invention claimed is:

1. A method of eliciting an immune response in a patient who has non-small cell lung carcinoma (NSCLC), lung cancer, and/or gastric cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of KIQEMQHFL (SEQ ID NO: 2), wherein the peptide is in a complex with an MHC molecule, and wherein the activated T cells are cytotoxic T cells produced by contacting T cells, in vitro, with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide.

2. The method of claim 1 , wherein the T cells are autologous to the patient.

3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.

4. The method of claim 1 , wherein the T cells are derived from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.

5. The method of claim 1 , further comprising expanding T cells in vitro.

6. The method of claim 1 , wherein the MHC molecule is a class I molecule.

7. The method of claim 1 , wherein the composition further comprises an adjuvant.

8. The method of claim 7 , wherein the adjuvant is selected from the group consisting of imiquimod, resiguimod, GM-CSP, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, CpG-containing oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, and particulate formations with poly(lactid co-glycolid) (PLG) and virosomes.

9. The method of claim 1 , wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide.

10. The method of claim 9 , wherein the antigen presenting cell is a dendritic cell or a macrophage.

11. The method of claim 1 , further comprising stimulating the activated T cells in the presence of an anti-CD28 antibody and IL-12 to clonally expand the T cells.

12. The method of claim 1 , wherein the population of activated T cells comprises CD8-positive cells.

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Weinschenk Toni
• Walter Steffen
• Fritsche Jens
• Song Colette
• Singh Harpreet

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07K7/06 Primary

  having 5 to 11 amino acids · CPC title

• C12N2502/11

  blood or immune system cells · CPC title